Production (Stage)
Cytophage Technologies Ltd.
CYTO.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -41.90% | -21.78% | 5.73% | -14.39% | 112.78% |
| Depreciation & Amortization | 34.37% | -3.34% | 53.54% | 53.08% | 64.30% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.71% | -19.41% | 11.26% | -8.94% | 33.20% |
| Operating Income | 32.71% | 19.41% | -11.26% | 8.94% | -33.20% |
| Income Before Tax | 74.56% | 6.64% | -9.88% | -5.70% | -270.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 74.56% | 6.64% | -9.88% | -5.70% | -270.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.56% | 6.64% | -9.88% | -5.70% | -270.17% |
| EBIT | 32.71% | 19.41% | -11.26% | 8.94% | -33.20% |
| EBITDA | 36.82% | 23.09% | -13.08% | 7.36% | -30.13% |
| EPS Basic | 76.49% | 25.68% | 12.94% | 17.16% | -212.75% |
| Normalized Basic EPS | 36.49% | 29.71% | 12.26% | 16.54% | -15.63% |
| EPS Diluted | 77.54% | 25.68% | 12.94% | 24.22% | -200.90% |
| Normalized Diluted EPS | 36.49% | 29.71% | 12.26% | 16.54% | -15.63% |
| Average Basic Shares Outstanding | 8.34% | 26.00% | 26.18% | 27.16% | 18.33% |
| Average Diluted Shares Outstanding | 8.34% | 26.00% | 26.18% | 27.16% | 18.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |